SHANGHAI, November 11, 2014 /PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced shareholder resolutions adopted at its annual general meeting of shareholders held in Hong Kong on November 11, 2014.
At the meeting, WuXi PharmaTech shareholders approved the re-election of incumbent Class A directors Xiaozhong Liu, Kian Wee Seah, and William R. Keller, each to serve a three-year term.
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec.
For more information, please contact:
Director of Investor Relations
Associate Director of Corporate Communications